Takeda Oncology
Mauricio Hernández is a seasoned professional with extensive experience in manufacturing and supply chain systems. Currently serving as the Sr Manager of Cell Therapy Manufacturing Systems at Takeda Oncology since August 2022, Mauricio previously held the position of Manufacturing & Supply Chain Systems Manager at Accenture from October 2019 to August 2022. Prior roles include MES SME at ESP Enterprise System Partners Ltd, supporting organizations such as Merck, and Sr MES Engineer at Zenith Technologies, focusing on Janssen Manufacturing Site. Mauricio also contributed as a Project and Plant Engineer at Bayer de México and gained initial experience through trainee positions at Bosch de México and Bayer de México. Educational qualifications include a degree in technology from Universidad del Valle de México and a certificate in Engineering Leadership from Cornell University.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.